Breaking News Instant updates and real-time market news.

CAH

Cardinal Health

$75.88

0.19 (0.25%)

16:54
10/05/16
10/05
16:54
10/05/16
16:54

Cardinal Health initiated with a Neutral at UBS

Target $82.

  • 31

    Oct

  • 03

    Nov

CAH Cardinal Health
$75.88

0.19 (0.25%)

09/27/16
COWN
09/27/16
NO CHANGE
COWN
Market Perform
Drag on drug distributors from brand inflation worries overdone, says Cowen
Cowen analyst Charles Rhyee said he views recent concerns over moderating brand inflation and their potential impact on drug distributors as "somewhat overblown," considering that he sees the issue as a 1%-2% headwind to adjusted EPS for the group. Additionally, Rhyee expects brand inflation to revert to normal levels once the current political rhetoric dies down. The analyst trimmed his price target on AmerisourceBergen (ABC) to $88 from $90, on Cardinal Health (CAH) to $86 from $89 and on McKesson (MCK) to $188 from $200 and keeps a Market Perform rating on all three stocks.
09/19/16
MSCO
09/19/16
NO CHANGE
MSCO
Drug Distributor price targets lowered at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser sees downside to December quarter earnings for distributors due to difficult year-over-year pricing comps. The analyst nows sees branded pricie moderation down 300 bps year-over-year versus 100bps previously as some drug manufacturers may be looking for moderating pricing practices following the Epipen controversy. As a result, Goldwasswer lowered estimates to reflect moderation in branded inflation and reduced price targets on McKesson (MCK) to $185 from $221, AmerisourceBergen (ABC) to $84 from $89, and Cardinal Health (CAH) to $82 from $91.
09/16/16
09/16/16
DOWNGRADE
Target $83

Neutral
Cardinal Health downgraded to Neutral on brand deflation at Goldman
As previously reported, Goldman downgraded Cardinal Health to Neutral from Conviction Buy and lowered its price target to $83 from $90. Analyst Robert Jones reduced his rating given softer brand price inflation that presents additional risk to earnings. Cardinal could face a $40M shortfall relative to guidance if brand inflation remains in the 7% range, versus the 10% assumed in FY17 guidance. Jones is now modeling 6% core growth in FY17, slightly below the 9% core growth expected in FY16. Further, the analyst believes margin improvement at Cordis will take more time than expected due to foreign exchange headwinds and a longer integration timeline.
09/16/16
GSCO
09/16/16
DOWNGRADE
GSCO
Neutral
Cardinal Health downgraded to Neutral from Conviction Buy at Goldman

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.